IHA comments urge collaboration on measuring health equity, delaying changes to Medicare organ transplantation payments, and expanding the cap on residency positions available under the CAA.
IHA submitted comments urging CMS to pursue National Quality Forum endorsement of proposed quality program measures.
IHA submitted comments requesting CMS continue monitoring public reporting of quality data impacted by COVID and ensure adequate resources for PAC providers transitioning to electronic standards.
IHA submitted comments urging CMS to delay and phase-in recoupment of overpayments made to SNF providers in FFY 2020, and explore revisions to the SNF VBP.
IHA submitted comments urging CMS to use its authority and influence to indefinitely maintain and expand telehealth access granted during the public health emergency.
IHA submitted comments objecting to his proposed rule, as it retroactively imposes a rule that the Supreme Court of the United States determined invalid.
IHA submitted comments addressing supervision levels, 340B payments, prior authorization policies, discontinuation of the inpatient only list, and Overall Star Ratings changes.
IHA submitted comments addressing CMS’ proposed utilization of hospital price transparency rule data, certain proposed changes to Medicare bad debt policies, and worksheet S-10 audits.
IHA submitted comments urging CMS to forgo proposals that would allow MA plans to assemble narrower provider networks.
IHA provides new, updated information on the Medicare Accelerated and Advance Payment Program amid COVID-19. See our FAQs.
IHA commented on the proposed collection of 340B provider acquisition costs.
IHA recommends 340B covered entities preserve their right to appeal current/future Medicare claims involving 340B drugs reimbursed at any level below the statutorily prescribed rate since Jan. 2018.
IHA commented on on the proposed rule that would establish new price transparency requirements.
IHA submitted comments to CMS on the the proposed rule establishing two new specialty care models specific to
radiation oncology and end-stage renal disease.
Comment letter to the Health Resources and Services Administration encouraging the agency to publish its final rule in time to meet the Jan. 1, 2019 proposed date.
Comments due to HRSA by Nov. 23